Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative NeoplasmsMagnus Björkholm, Ola Landgren, Sigurður Y. Kristinsson et al.|Journal of Clinical Oncology|2011Cited by 244
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimensMats Merup, Vladimir Lazarević, Hareth Nahi et al.|British Journal of Haematology|2006Cited by 56
Genetic variation in <i><scp>IL</scp>28B</i> (<i><scp>IFNL</scp>3</i>) and response to interferon‐alpha treatment in myeloproliferative neoplasmsMarie Lindgren, Björn Andréasson, Jan Samuelsson et al.|European Journal Of Haematology|2018Cited by 23
Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndromeDolores Subirá, Dunia de Miguel, Canan Alhan et al.|Annals of Hematology|2021Cited by 7
A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of TherapyMarie Lindgren, Björn Andréasson, Jan Samuelsson et al.|Blood|2014Cited by 3